Aryl ester prodrugs of cyclic HPMPC. I: Physicochemical characterization and in vitro biological stability

Pharmaceutical Research

Volumn 16, Issue 11, 1999, Pages 1687-1693

  Oliyai, Reza ^a   Shaw, Jeng Pyng ^a,b   Sueoka Lennen, Cathy M ^a   Cundy, Kenneth C ^a   Arimilli, Murty N ^a   Jones, Robert J ^a   Lee, William A ^a  

^a GILEAD SCIENCES   (United States)

^b Advanced Medicine Inc   (United States)

Author keywords

Cidofovir; Cyclic HPMPC; Cyclic phosphonate; Nucleotides; Prodrug; Reactivity; Salicylate esters

Indexed keywords

[[2 (4 AMINO 2 OXO 1(2H) PYRIMIDINYL) 1 (HYDROXYMETHYL)ETHOXY]METHYL]PHOSPHONIC ACID; CIDOFOVIR; PRODRUG; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONFORMATIONAL TRANSITION; DRUG CONFORMATION; DRUG DEGRADATION; DRUG DETERMINATION; DRUG SOLUBILITY; DRUG STABILITY; LIPID SOLUBILITY; MOLECULAR STABILITY; PARTITION COEFFICIENT; PRIORITY JOURNAL;

ANIMALS; ANTIVIRAL AGENTS; BLOOD; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOSINE; DOGS; DRUG STABILITY; HUMANS; HYDROLYSIS; INTESTINES; LIGANDS; LIVER; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PRODRUGS; SALICYLATES; SOLUBILITY; STEREOISOMERISM; SWINE; TIME FACTORS;

EID: 0032706566     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018945713623     Document Type: Article

References (25)

1. 1. L. Naesens, R. Snoeck, J. Balzarini, J. Neyts, and E. De Clercq. HPMPC (cidofovir), PMEA (adefovir) and related acylic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem. Chemother. 8:1-23 (1997).
2. 2. M. J. M. Hitchcock, H. S. Jaffe, J. C. Martin, and R. J. Stagg. Review - Antiviral portrait series. Cidofovir, a new agent with potent anti-herpesvírus activity. Antiviral Chem. Chemother. 7:115-127 (1996).
3. 3. K. C. Cundy, A. M. Bidgood, G. Lynch, J.-P. Shaw, L. Griffin, and W. A. Lee. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab. Disp. 24:745-752 (1996).
4. 4. K. C. Cundy, P. Barditch-Crovo, R. E. Walker, A. C. Coller, D. Ebeling, J. Toole, and H. S. Jaffe. Clinical pharmacokinetics of Adefovir in human immunodeficiency virus type I-infected patients. Antimicr. Agents Chemother. 39:2401-2405 (1995).
5. 5. J. -P. Shaw, M. S. Louie, V. V. Krishnamurthy, M. A. Arimilli, R. J. Jones, Alison M. Bidgood, W. A. Lee, and K. C. Cundy. Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats. Drug Metab. Disp. 25:361-366 (1997).
6. 6. J.-P. Shaw, C. M. Sueoka, R. Oliyai, W. A. Lee, M. N. Arimilli, C. U. Kim, and K. C. Cundy. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl] adenine (PMPA) in dogs. Pharm. Res. 12:1824-1829 (1997).
7. 7. J. P. Krise and V. J. Stella. Prodrugs of phosphates, phosphonates, and phosphinates. Adv. Drug Del. Rev. 19:287-310 (1996).
8. 8. P. Barditch-Crovo, J. Tool, C. W. Hendrix, K. C. Cundy, H. S. Jaffe, and P. S. Lietman. Anti-juman immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of Adefovir Dipivoxil (9-2-[bis-pivalotloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J. Infect. Dis. 176:406-413 (1997).
9. 9. N. Bischofberger, M. J. M. Hitchcock, M. S. Chen, K. C. Cundy, D. Barkhimer, K. M. Kent, S. A. Lacy, W. A. Lee, Z.-H. Li, M. Louie, D. B. Mendel, D. S. Smee, and J. L. Smith. 1-[((S)-2-Hydroxy-2-Oxo-1,4,2-Dioxaphosphorinan-5-yl)Methyl]Cytosine, an intracellular prodrug for (S)-1-(3-Hydroxy-2-(Phosphonylmethoxypropyl)Cytosine with improved therapeutic index in vivo. Antimicr. Agents Chemother. 38:2387-2391(1994).
10. 10. M. J. M. Hitchcock, S. A. Lacy, J. R. Lindsey, and E. R. Kern. The cyclic congener of cidofovir has reduced nephrotoxicity in three species. Antiviral Res. 26:A358 (1995).
11. 11. D. B. Mendel, T. Cihlar, K. Moon, and M. S. Chen. Cyclic HPMPC is converted to cidofovir by an intracellular cyclic CMP phosphodiesterase. Antimicr. Agents Chemother. 41:641-646 (1997).
12. 12. W. A. Lee, J.-P. Shaw, A. M. Bidgood, G. Lynch, E. Eisenberg, and K. C. Cundy. Tissue distribution and bioavailability of cyclic HPMPC, an intracellular prodrug of HPMPC. Antiviral Res. 26:A340 (1995).
13. 13. S. Kelly and L. G. Butler. Enzymic hydrolysis of phosphonate esters. Reaction mechanism of intestinal 5′-nucleotide phosphodiesterase. Biochemistry 16:1102-1104 (1997).
14. 14. S. Kelly, D. E. Dardinger, and L. G. Butler. Hydrolysis of phosphonate esters catalyzed by 5′-nucleotide phosphodiesterase. Biochemistry 14:4983-4988 (1975).
15. 15. S. Khamnei and P. F. Torrence. Neighboring group catalysis in the design of nucleotide prodrugs. J. Med. Chem. 39:4109-4115 (1996).
16. 16. G. Powis. The use of human liver for foreign compound metabolism and toxicity studies. Drug Metab. Rev. 20:379-394 (1989).
17. 17. M. N. Arimilli, R. J. Jones, and E. Prisbe. Nucleotide analogs. U.S. Patent 5,717,095 (1998.)
18. 18. I. M. Kovach, M. Larson, and R. L. Schowen. Catalytic recruitment in the inactivation of serine protease by phosphonate esters. Recruitment of acid-base catalysis. J. Am. Chem. Soc. 108:5490-5495 (1986).
19. 19. Q. Zhao, I. M. Kovach, A. Bencsura, and A. Papathanassiu. Enantioselective and reversible inhibition of Trypsin and α-Chymotrypsin by phosphonate esters. Biochemistry 33:8128-8138 (1994).
20. 20. J.-W. Chang and D. G. Gorenstein. Stereoelectronic effects on the conformation and kinetics of nucleophilic displacement reactions in epimeric six-membered ring phosphonate diesters. Tetrahedron. 43:5187-5196 (1987).
21. 21. R. Rowell and D. G. Gorenstein. Multiple structure-reactvity correlations in the hydrolysis of epimeric 2-(aryloxy)-2-oxydioxaphosphorinanes. Stereoelectronic effects. J. Am. Chem. Soc. 103:5894-5902 (1981).
22. 22. S. W. Benson, F. R. Cruickshank, D. M. Golden, G. R. Haugen, H. E. O'Neal, A. S. Rodgers, R. Shaw, and R. Walsh. Additivity rules for the estimation of thermodymamical properties. Chemical Rev. 69:279-324 (1969).
23. 23. J. R. Cox and O. B. Ramsay. Mechanism of nucleophilic substitution in phosphate esters. Chem. Rev. 64:317-352 (1964).
24. 24. F. H. Westheimer. Pseudo-Rotation in the hydrolysis of phosphate esters. Acc. Chem. Res. 1:70-78 (1968).
25. 25. K. C. Cundy, C. Sueoka, G. R. Lynch, L. Griffin, W. A. Lee, and J.-P. Shaw. Pharmacokinetics and bioavailability of the antihuman immunodeficiency virus nucleotide analog PMPA in dogs. Antimicr. Agents Chemother. 42:687-690 (1998).